TRT on TikTok: separating testosterone facts from fitness bro fiction

What did @big.chocky actually say?

The creator, known as Chocky, disclosed on TikTok that he was prescribed testosterone replacement therapy (TRT) three and a half years ago after self-reported drug and alcohol use damaged his natural testosterone production. He framed this as radical honesty, challenged critics who call him a "juice head," and made two specific medical claims: first, that the FDA recently removed the black box warning from testosterone, and second, that TRT "makes you healthier if your levels are fucking right." He also argued that lifestyle factors like obesity and poor diet are more dangerous than medically supervised TRT. The disclosure itself is genuinely refreshing in a TikTok fitness space full of vague "optimisation" talk. But the medical claims deserve a closer look.

Does the science back this up?

Partially, but the FDA claim is garbled enough to be misleading. Here is what is actually true: TRT in men with clinically confirmed hypogonadism does improve multiple health markers. But the FDA story is more complicated than a clean removal of a black box warning.

On TRT benefits: a 2023 landmark randomised controlled trial, Lincoff et al. in the New England Journal of Medicine (the TRAVERSE trial), found that testosterone therapy in middle-aged and older men with hypogonadism and cardiovascular risk factors did not increase the rate of major adverse cardiovascular events compared to placebo. That is genuinely significant. Earlier observational studies had raised serious cardiac concerns, and the TRAVERSE data pushed back on the worst-case scenarios.

On metabolic benefits: Traish et al. (2014, Journal of Sexual Medicine) and subsequent meta-analyses have shown that testosterone normalisation in hypogonadal men can improve insulin sensitivity, reduce visceral fat, and improve mood, which tracks with what Chocky describes about his own wellbeing.

However, TRT is not uniformly "healthier" for everyone. Risks including erythrocytosis (elevated red blood cell count), suppression of spermatogenesis, and potential prostate effects remain real clinical considerations that require monitoring.

What did they get wrong (or right)?

The FDA black box warning claim is where things get sloppy. The FDA has not fully removed the black box warning from testosterone products. What actually happened: in 2015, the FDA added a warning about cardiovascular risks and abuse potential. Following the TRAVERSE trial results in 2023, the FDA reviewed the cardiovascular language and proposed updates. As of early 2025, the FDA removed the general cardiovascular risk warning that had been added in 2015 for hypogonadal men, based on TRAVERSE data. But the warning about abuse potential and the requirement for a specific indication remain. Saying the FDA "removed the black label" without that nuance makes it sound like testosterone got a clean safety bill of health across the board. It did not.

What Chocky got right: regular blood monitoring is exactly what responsible TRT management looks like. His mention of checking bloods and blood pressure aligns with clinical best practice. His framing that lifestyle disease may carry equal or greater mortality risk than monitored TRT for hypogonadal men is actually defensible in the literature.

What he got wrong or oversimplified: claiming TRT "makes you healthier" as a general statement ignores that this is only true for men with confirmed low testosterone. Taking testosterone when levels are normal does not produce the same benefits and introduces real risks.

What should you actually know?

TRT is a legitimate, well-studied medical treatment for hypogonadism, defined clinically as consistently low serum testosterone combined with symptoms. It is not a wellness supplement for everyone who feels tired or wants to build muscle. The TRAVERSE trial (Lincoff et al., 2023, NEJM) is the best evidence we have on cardiovascular safety, and it is reassuring for the specific population studied: men with hypogonadism and pre-existing cardiovascular risk factors. It is not a licence to dismiss all TRT risks.

If you are considering TRT, you need baseline bloodwork including total testosterone, free testosterone, LH, FSH, haematocrit, PSA, and a lipid panel. You need two morning blood draws on separate days to confirm low levels. And you need an actual prescribing clinician, not a TikTok video, guiding that decision.

• Chocky's transparency about his history is valuable and unusual in this content space.
• His monitoring habits (regular bloods, blood pressure checks) reflect responsible practice.
• The FDA warning claim is oversimplified and should not be repeated without the specific context of the 2023 TRAVERSE-driven update.
• "Makes you healthier" only applies to men with confirmed hypogonadism, not the general population.